STOCK TITAN
  1. Home
  2. Sec-filings
  3. WGSWW
  4. [Form 4] GeneDx Holdings Corp. Insider Trading Activity

[Form 4] GeneDx Holdings Corp. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.

Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.

Transacciones de insiders reportadas para GeneDx Holdings Corp. (WGS) muestran que Katherine Stueland recibió 18,750 unidades de acciones restringidas (RSU) el 16/09/2025, que se convertirán en acciones comunes de Clase A al momento de la liquidación sin contraprestación en efectivo, y vendió 10,501 acciones de acciones comunes de Clase A el mismo día a un precio medio ponderado de $121.4727 por acción, como parte de una operación en bloque. La venta se divulgó como una transacción de "vender para cubrir" para satisfacer la retención de impuestos vinculada al vesting de las RSU y no fue discrecional. Después de estas transacciones, la persona informante poseía directamente 14,578 acciones de acciones comunes de Clase A y, por separado, era titular de RSU que representan hasta 444,539 acciones y de opciones por 107,610 acciones, sujeta a sus términos de vesting.

GeneDx Holdings Corp. (WGS)에 대한 내부자 거래 보고에 따르면 Katherine Stueland는 2025년 9월 16일 18,750주 제한 주식 단위(RSU)10,501주의 Class A 보통주를 가중평균가 $121.4727 달러에 블록 거래의 일부로 매각했습니다. 이 매도는 RSU의 베스팅과 관련된 세금 원천징수를 충족시키기 위한 "cover를 위한 매도"로 공시되었으며 재량적이었습니다. 이러한 거래 후, 보고자_PERSON은 Class A 보통주를 14,578주 직접 소유하고 있으며, 별도로 RSU가 최대 444,539주를 대표하고, 주식매수선택권이 107,610주를 보유하고 있으며, 이는 각각의 vesting 조건에 따릅니다.

Des transactions d’initiés rapportées pour GeneDx Holdings Corp. (WGS) montrent que Katherine Stueland a reçu 18 750 RSU (unités d’actions restreintes) le 16/09/2025 qui se convertiront en actions ordinaires de Classe A au règlement sans contrepartie en espèces, et a vendu 10 501 actions ordinaires de Classe A le même jour à un prix moyen pondéré de $121,4727 par action, dans le cadre d’une opération en bloc. La vente a été divulguée comme une transaction « vendre pour couvrir » afin de satisfaire la retenue fiscale liée au vesting des RSU et n’était pas discrétionnaire. Après ces transactions, la personne déclarante détenait directement 14 578 actions ordinaires de Classe A et, séparément, détenait des RSU représentant jusqu’à 444 539 actions et des options pour 107 610 actions, sous réserve des conditions de vesting.

Insider-Transaktionen gemeldet für GeneDx Holdings Corp. (WGS) zeigen, dass Katherine Stueland am 16.09.2025 18.750 RSUs erhielt, die bei der Abwicklung in Class-A-Stammaktien umgewandelt werden, ohne Barabgeltung, und dass sie am selben Tag 10.501 Class-A-Stammaktien zu einem gewichteten Durchschnittspreis von $121,4727 pro Aktie im Rahmen eines Blockdeals verkaufte. Der Verkauf wurde als „Sell to cover“-Transaktion bekanntgegeben, um die steuerliche Vorababzugspflicht im Zusammenhang mit dem RSU-Vesting zu erfüllen, und war nicht diskretionär. Nach diesen Transaktionen hielt die meldende Person direkt Beneficial Class-A-Stammaktien im Umfang von 14.578 Aktien und separat RSUs, die bis zu 444.539 Aktien repräsentieren, sowie Optionen über 107.610 Aktien, vorbehaltlich der Vesting-Bedingungen.

التعاملات الداخلية المبلّغ عنها لشركة GeneDx Holdings Corp. (WGS) تُظهر أن كاثرين ستويلاند تلقت 18,750 وحدة أسهم مقيدة (RSUs) في 16/09/2025 التي ستتحول إلى أسهم عادية من الفئة A عند التسوية دون مقابل نقدي، وأنها باعت 10,501 سهماً من أسهم الفئة A العادية في اليوم نفسه في إطار صفقة كبيرة بسعر وزني قدره $121.4727 دولار للسهم. وقد أُعلن عن البيع كصفقة "بيع لتغطية" لتلبية الاستقطاع الضريبي المرتبط ب vesting RSU ولم يكن اختياره شخصياً. بعد هذه المعاملات، أصبح للشخص المبلغ مباشرةً ملكية مفيدة لـ 14,578 سهم من أسهم الفئة A العادية، وبشكل منفصل مالك RSUs تمثل حتى 444,539 سهم وخيارات لـ 107,610 سهم، رهناً بشروط vesting الخاصة بها.

GeneDx Holdings Corp.（WGS）的内部交易报告显示，Katherine Stueland 于 2025-09-16 获得了 18,750 份受限股票单位（RSU），在结算时无需现金对价即可转成 Class A 普通股，并在同日以加权平均价格 $121.4727 美元/股出售了 10,501 股 Class A 普通股，属于一笔大宗交易。该出售被披露为“为覆盖”税务而出售，以满足与 RSU 归属相关的预扣税，且并非出于自由裁量。经这几笔交易后，报告人直接受益持有 14,578 股 Class A 普通股，另外，持有 RSU 最多代表 444,539 股，以及 107,610 股的期权，均受其 vesting 条款约束。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine "sell to cover" tax-sale tied to RSU settlement; insider still holds significant equity exposure via RSUs and options.

The Form 4 reports a non-discretionary sale of 10,501 shares at a weighted-average price of $121.4727 to satisfy withholding obligations arising from the vesting/settlement of 18,750 RSUs. Such tax-driven sales are common and do not necessarily signal a change in management conviction. Material ongoing equity exposure remains: the reporting person beneficially owns 14,578 shares plus RSUs convertible to up to 444,539 shares and options for 107,610 shares, subject to vesting schedules. The disclosure is detailed and includes an undertaking to provide per-price breakdowns for the block trade.

TL;DR: Transaction is administrative (tax withholding) and governance disclosure is complete; significant unvested equity aligns executive incentives with shareholders.

The filing documents receipt of 18,750 RSUs exercisable for Class A shares at $0 consideration and a contemporaneous sale to cover taxes. The form identifies the reporting person as both a director and the Chief Executive Officer, which underscores the governance importance of clearly reporting such transactions. The disclosure of aggregate unvested RSUs (444,539) and options (107,610) provides transparency on potential future dilution and executive alignment. No discretionary insider selling is reported.

Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.

Transacciones de insiders reportadas para GeneDx Holdings Corp. (WGS) muestran que Katherine Stueland recibió 18,750 unidades de acciones restringidas (RSU) el 16/09/2025, que se convertirán en acciones comunes de Clase A al momento de la liquidación sin contraprestación en efectivo, y vendió 10,501 acciones de acciones comunes de Clase A el mismo día a un precio medio ponderado de $121.4727 por acción, como parte de una operación en bloque. La venta se divulgó como una transacción de "vender para cubrir" para satisfacer la retención de impuestos vinculada al vesting de las RSU y no fue discrecional. Después de estas transacciones, la persona informante poseía directamente 14,578 acciones de acciones comunes de Clase A y, por separado, era titular de RSU que representan hasta 444,539 acciones y de opciones por 107,610 acciones, sujeta a sus términos de vesting.

GeneDx Holdings Corp. (WGS)에 대한 내부자 거래 보고에 따르면 Katherine Stueland는 2025년 9월 16일 18,750주 제한 주식 단위(RSU)10,501주의 Class A 보통주를 가중평균가 $121.4727 달러에 블록 거래의 일부로 매각했습니다. 이 매도는 RSU의 베스팅과 관련된 세금 원천징수를 충족시키기 위한 "cover를 위한 매도"로 공시되었으며 재량적이었습니다. 이러한 거래 후, 보고자_PERSON은 Class A 보통주를 14,578주 직접 소유하고 있으며, 별도로 RSU가 최대 444,539주를 대표하고, 주식매수선택권이 107,610주를 보유하고 있으며, 이는 각각의 vesting 조건에 따릅니다.

Des transactions d’initiés rapportées pour GeneDx Holdings Corp. (WGS) montrent que Katherine Stueland a reçu 18 750 RSU (unités d’actions restreintes) le 16/09/2025 qui se convertiront en actions ordinaires de Classe A au règlement sans contrepartie en espèces, et a vendu 10 501 actions ordinaires de Classe A le même jour à un prix moyen pondéré de $121,4727 par action, dans le cadre d’une opération en bloc. La vente a été divulguée comme une transaction « vendre pour couvrir » afin de satisfaire la retenue fiscale liée au vesting des RSU et n’était pas discrétionnaire. Après ces transactions, la personne déclarante détenait directement 14 578 actions ordinaires de Classe A et, séparément, détenait des RSU représentant jusqu’à 444 539 actions et des options pour 107 610 actions, sous réserve des conditions de vesting.

Insider-Transaktionen gemeldet für GeneDx Holdings Corp. (WGS) zeigen, dass Katherine Stueland am 16.09.2025 18.750 RSUs erhielt, die bei der Abwicklung in Class-A-Stammaktien umgewandelt werden, ohne Barabgeltung, und dass sie am selben Tag 10.501 Class-A-Stammaktien zu einem gewichteten Durchschnittspreis von $121,4727 pro Aktie im Rahmen eines Blockdeals verkaufte. Der Verkauf wurde als „Sell to cover“-Transaktion bekanntgegeben, um die steuerliche Vorababzugspflicht im Zusammenhang mit dem RSU-Vesting zu erfüllen, und war nicht diskretionär. Nach diesen Transaktionen hielt die meldende Person direkt Beneficial Class-A-Stammaktien im Umfang von 14.578 Aktien und separat RSUs, die bis zu 444.539 Aktien repräsentieren, sowie Optionen über 107.610 Aktien, vorbehaltlich der Vesting-Bedingungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Stueland Katherine
(Last) (First) (Middle)
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST., NORTH TOWER, 6TH FLOOR
(Street)
STAMFORD CT 06902
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/16/2025 M 18,750 A $0(1) 25,079 D
Class A Common Stock 09/16/2025 S(2) 10,501 D $121.4727(3) 14,578(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 09/16/2025 M 18,750 (5) (5) Class A Common Stock 18,750 $0 112,500 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The price reported is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $118.28 to $123.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 with regard to the block trade.
4. Following the reported sales, in addition to the 14,578 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 444,539 shares of Class A common stock and options to purchase up to an aggregate of 107,610 shares of Class A common stock, which RSUs and options vest according to their respective terms.
5. 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Bridget Brown, Attorney-in-Fact 09/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Katherine Stueland report on Form 4 for GeneDx (WGSWW)?

The filing reports receipt of 18,750 RSUs on 09/16/2025 and a contemporaneous sale of 10,501 Class A shares at a weighted-average price of $121.4727 to cover tax withholding.

Why were shares sold by the reporting person?

The sale was a sell-to-cover transaction to satisfy tax withholding obligations related to the vesting and settlement of RSUs and was not a discretionary sale.

How many shares does the reporting person beneficially own after the transaction?

After the reported transactions the reporting person beneficially owned 14,578 shares of Class A common stock plus RSUs representing up to 444,539 shares and options for 107,610 shares, subject to vesting.

What price range applied to the block trade that included the reported sale?

The block trade sold shares at prices ranging from $118.28 to $123.07, inclusive; the Form 4 lists a weighted-average price of $121.4727.

When did the transactions occur?

The transactions reported on the Form 4 occurred on 09/16/2025.
Stock WGSWW logo
GeneDx Holdings Corp

NASDAQ:WGSWW

WGSWW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

WGSWW Latest SEC Filings

WGSWW Stock Data

Services-health Services
STAMFORD